Capricor, Inc., a Los Angeles, CA-based biotechnology company that aims to create cardiac stem cell treatments to regenerate the heart and improve its function, raised nearly $2m from Broadview Ventures and private individual investors.
The company intends to use the funds to develop the U.S. clinical trials for cardiac therapies based on its proprietary mix of stem cells derived from cardiac tissue, which aim to regenerate damaged areas of the heart and improve heart function.
Capricor intends to begin Phase II/III clinical trials at sites throughout the U.S. in early 2011 in partnership with institutions including Cedars-Sinai Medical Center and Johns Hopkins.
Led by co-founder and CEO Linda Marbán, Ph.D., the company is working to develop and commercialize cardiac stem cell therapies that are based on Cardiospheres™, its proprietary mixture of cells from the heart itself.
The team includes cardiac stem cell researchers and advisory board members, including founder Eduardo Marbán, M.D., Ph.D.